Artificial Intelligence, Biotech, Clinical Development, Clinical studies, Drug Development, Partnerships & Funding, Pharmaceuticals and therapeutics, Research & Development

Immunai has entered into a collaboration with Bristol Myers Squibb aimed at applying artificial intelligence to support immune-driven clinical development programmes.

Under the agreement, Immunai will use its immune system intelligence platform, AMICA-OS, to analyse complex immune data generated in Bristol Myers Squibb clinical studies. The collaboration is designed to generate immune-centric insights that could help inform clinical decision-making across multiple stages of drug development.

The companies said the work will focus on improving understanding of patient biology and variability in treatment response by analysing high-dimensional immune datasets. Immunai’s technology is intended to support activities such as elucidating immune-related mechanisms of action, patient stratification, biomarker discovery and data-informed development decisions.

Immunai specialises in mapping the human immune system by integrating multi-omic and single-cell data with AI-based modelling. Through this collaboration, its immune system models and computational infrastructure will be applied within Bristol Myers Squibb’s ongoing clinical development efforts, with an initial focus on extracting deeper insights from immune data already being collected in trials.

Noam Solomon, ceo of Immunai, said: “Understanding the immune system at the level required to guide clinical development remains one of the most complex challenges in drug development.” He added: “Through our collaboration with BMS, we will apply AMICA-OS to translate complex immune data into actionable insights that can support clinical decision-making and ultimately help advance better therapies for patients.”

The collaboration reflects growing interest across the pharmaceutical sector in using AI to improve interpretation of biological complexity, particularly in areas such as oncology, immunology and cell therapy, where immune dynamics play a central role in both efficacy and safety. By applying immune-focused analytics to clinical datasets, the companies aim to improve how immune responses are measured and understood during development.

Bryan Campbell, senior vice president and head of program leadership, hematology, oncology and cell therapy at Bristol Myers Squibb, said the collaboration aligns with the company’s broader approach to innovation in clinical research. He said: “At Bristol Myers Squibb, we are focused on leveraging innovative approaches that deepen our understanding of patient biology and treatment response.” He added: “Our collaboration with Immunai will enable the use of advanced AI technologies to generate meaningful immune insights from clinical data, supporting our efforts to advance the development of transformative medicines.”

The companies indicated that the collaboration could expand beyond its initial scope. As additional clinical programmes generate immune data, Immunai’s platform may be applied more broadly to support immune-driven development strategies across different therapeutic areas.

Neither company disclosed financial terms of the agreement. The collaboration does not involve co-development of a specific therapeutic asset, but instead focuses on analytical support designed to enhance decision-making during clinical development.

As immune profiling becomes increasingly embedded in clinical trial design, partnerships such as this highlight how AI-based platforms are being positioned as enabling technologies rather than standalone products. For Bristol Myers Squibb, the collaboration offers a way to deepen immune insight across its pipeline, while for Immunai it represents further validation of its immune system intelligence approach in large-scale pharmaceutical development.